Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ionis Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was €2,559.2 Mil.
Ionis Pharmaceuticals's quarterly Total Liabilities
increased
from Sep. 2025 (€2,057.69 Mil) to Dec. 2025 (€2,591.67 Mil) but then
declined
from Dec. 2025 (€2,591.67 Mil) to Mar. 2026 (€2,559.15 Mil).
Ionis Pharmaceuticals's annual Total Liabilities
declined
from Dec. 2023 (€2,387.31 Mil) to Dec. 2024 (€2,306.63 Mil) but then
increased
from Dec. 2024 (€2,306.63 Mil) to Dec. 2025 (€2,591.67 Mil).
Ionis Pharmaceuticals Total Liabilities Related Terms
Ionis Pharmaceuticals Total Liabilities Historical Data
* Premium members only.
The historical data trend for Ionis Pharmaceuticals's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ionis Pharmaceuticals Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
Ionis Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of €2,559.2 Mil mean?
Ionis Pharmaceuticals (FRA:ISI) has a Total Liabilities of €2,559.2 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Total Liabilities too high?
Ionis Pharmaceuticals' current Total Liabilities is €2,559.2 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Total Liabilities compare to EXEL and BBIO?
Ionis Pharmaceuticals' Total Liabilities of €2,559.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Total Liabilities is €2,559.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Fairly Valued. The stock's GF Value™ is €47.74, compared to a current price of €50.46 — trading 5.7% above its estimated fair value. The current Total Liabilities is €2,559.2 Mil. Ionis Pharmaceuticals' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current Total Liabilities is €2,559.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?
Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued.
The current stock price of €50.46 is trading 5.7% above its estimated GF Value™ of €47.74.
GuruFocus considers Ionis Pharmaceuticals to be Fairly Valued.
Key valuation signals for FRA:ISI:
Total Liabilities: €2,559.2 Mil
GF Value™: €47.74 vs. price of €50.46 (5.7% above fair value)
No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
72GF Score
Get the complete analysis for FRA:ISI
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ISI has been successfully added to your 
